Search for: "Novartis Pharmaceuticals Corp."
Results 161 - 180
of 366
Sorted by Relevance
|
Sort by Date
7 Nov 2014, 5:52 am
Novartis Pharmaceuticals Corp., 952 F. [read post]
17 Sep 2021, 12:18 pm
’” The court emphasized that evidence of “motivation to combine” and “expectation of success” are separate legal requirements, citing its 2019 decision in Novartis Pharmaceuticals Corp. v. [read post]
2 Mar 2012, 6:52 am
Stryker Corp. [read post]
9 Aug 2012, 5:00 am
Nittany Pharmaceuticals (?) [read post]
26 Mar 2012, 4:00 am
Corp., No. 06-4049-CV (W.D. [read post]
2 Sep 2009, 11:22 pm
Novartis Corp., 378 F. [read post]
12 Jul 2022, 2:08 am
Corp. v. [read post]
5 Jul 2013, 5:00 am
Ortho Pharmaceutical Corp., 661 N.E.2d 352, 355 (Ill. 1996). [read post]
23 Nov 2007, 9:00 am
Astra's Data Exclusivity prevents a European generic launch, until at least 2010.: (Generic Pharmaceuticals & IP), Iressa (gefitinib) - Astrazeneca's Indian patent application rejected: (Generic Pharmaceuticals & IP), Ziagen (Abacavir Hemisulfate Salt) -GSK's application [872/CAL/98; corresponding to Orange Book listed US6294540] opposed by Indian Network for People living with HIV/ AIDS and then withdrawn by GSK: (Generic Pharmaceuticals… [read post]
14 Jul 2010, 6:47 pm
Sun Pharmaceutical Industries, Inc. [read post]
21 Aug 2008, 9:43 pm
Novartis Pharmaceuticals Corp., the court reconsidered its ruling and decided under all the circumstances there was still not an Article III case or controversy.The Federal Circuit affirmed. [read post]
20 Dec 2018, 10:14 am
” See Novartis Pharmaceuticals Corp. v. [read post]
2 Aug 2009, 10:00 pm
Novartis Pharmaceuticals Corp., No. [read post]
2 Feb 2009, 9:51 am
This January 2008 press release from KV Pharmaceutical, the parent company of ETHEX, includes a list of the more than 60 generic drugs being recalled by ETHEX. [read post]
18 Apr 2014, 11:00 am
Novartis Pharmaceuticals Corp., No. 13-15433, 2014 U.S. [read post]
5 Jul 2011, 1:44 pm
The patents were owned jointly by MedImmune and MRC, who alleged that they had been infringed by Novartis’ sales of ranibizumab, a pharmaceutical product sold under the trade mark Lucentis and is approved for the treatment of an eye condition known as wet age-related macular degeneration. [read post]
18 Nov 2009, 4:57 am
Corp. v. [read post]
18 Nov 2009, 4:57 am
Corp. v. [read post]
18 Nov 2009, 4:57 am
Corp. v. [read post]
7 Jun 2007, 10:52 am
Sandoz Pharmaceuticals Corp., 77 F. [read post]
